Clinical trials: Clear Cell Renal Cancer
Clear-cell Metastatic Renal Cell Carcinoma
Targeted Therapy With or Without Nephrectomy in Metastatic Renal Cell Carcinoma: Liquid Biopsy for Biomarkers Discovery
Two randomized trials in the cytokine era clearly showed that cytoreductive nephrectomy (CN) had a role in metastatic renal cell carcinoma (mRCC) increasing life expectancy.
- Trial name
- TARIBO (NCT02535351)
- Testing
- sunitinib or pazopanib, Cytoreductive nephrectomy
- Where
- Italy
- Volunteers
- 13 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Clear Cell Renal Cell Carcinoma, Sarcomatoid Renal Cell Carcinoma
An Investigational Scan (89Zr-DFO-GmAb PET/CT) Compared to Contrast-Enhanced CT for the Detection of Recurrent Clear Cell Renal Cell Cancer After Surgery Comparing Carbonic Anhydrase IX (CAIX) PET CT to Conventional PET CT for Post-Op Staging in Kidney Cancer
This phase II trial compares the safety and effectiveness of 89Zr-DFO-GmAb positron emission tomography (PET)/computed tomography (CT) compared to contrast-enhanced CT after surgery in detecting clear cell renal cell cancer that…
- Conditions
- Clear Cell Renal Cell Carcinoma, Sarcomatoid Renal Cell Carcinoma, Stage II Renal Cell Cancer, Stage III Renal Cell Cancer
- Trial name
- NCT06447103
- Testing
- Biospecimen Collection, Bone Scan, Computed Tomography
- Where
- United States
- Volunteers
- 91 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Clear Cell Renal Cell Carcinoma
A Phase 1 Trial of ADI-270 in ccRCC
This is a Phase 1 multicenter, open-label, dose escalation, and dose expansion study of ADI-270 - an Engineered gamma-delta Chimeric Receptor [CAR] Vδ1 T Cell product Targeting CD70 - in patients with R/R ccRCC.
- Trial name
- NCT06480565
- Testing
- ADI-270, Fludarabine, Cyclophosphamide
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Adicet Therapeutics
Clear Cell Renal Cell Carcinoma, Renal Cell Carcinoma (RCC)
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
This phase III trial compares the effect of adding tivozanib to standard therapy pembrolizumab versus pembrolizumab alone for the treatment of patients with high-risk renal cell carcinoma (RCC).
- Conditions
- Clear Cell Renal Cell Carcinoma, Renal Cell Carcinoma (RCC), Stage II Renal Pelvis Cancer AJCC v8, Stage III Renal Pelvis Cancer AJCC v8
- Trial name
- STRIKE (NCT06661720)
- Testing
- Pembrolizumab, Tivozanib, Biospecimen Collection
- Where
- 429 sites in United States
- Volunteers
- 1,040 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Carcinoma, Renal Cell
ATN-161 in Advanced Renal Cell Cancer
The purpose of this study is to determine an active dose of ATN-161 for future studies while establishing preliminary evidence of effectiveness in patients with renal cell cancer.
- Trial name
- NCT00131651
- Testing
- ATN-161
- Where
- 4 sites in United States
- Volunteers
- 36 people
- Sponsor
- Attenuon
Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer
Autologous Dendritic Cells in Treating Patients With Metastatic Kidney Cancer
This phase I trial studies the side effects and best dose of autologous dendritic cells in treating patients with metastatic kidney cancer.
- Conditions
- Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer, Stage IV Renal Cell Cancer
- Trial name
- NCT01826877
- Testing
- AdGMCAIX-transduced autologous dendritic cells, therapeutic autologous dendritic cells, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Kidney Cancer
Studying Tumor Tissue Samples From Patients Who Have Undergone Surgery for Localized Kidney Cancer
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00908739
- Testing
- gene expression analysis, immunohistochemistry staining method, laboratory biomarker analysis
- Sponsor
- Case Comprehensive Cancer Center
Advanced Cancer
A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer
The reason for this study is to see if the CD73 inhibitor LY3475070 alone or in combination with pembrolizumab is safe and effective in participants with advanced cancer.
- Trial name
- NCT04148937
- Testing
- LY3475070, Pembrolizumab
- Where
- 12 sites in United States, Australia and 1 more
- Volunteers
- 52 people
- Sponsor
- Eli Lilly and Company
Sarcoma, Clear Cell, Sarcoma, Alveolar Soft Part
Vaccine Trial for Clear Cell Sarcoma, Pediatric Renal Cell Carcinoma, Alveolar Soft Part Sarcoma and Children With Stage IV Melanoma
The purpose of this study is to learn if a vaccine made from the patient's own tumor cells, then genetically modified to secrete granulocyte-macrophage colony-stimulating factor (GM-CSF), will delay or stop the growth of the…
- Conditions
- Sarcoma, Clear Cell, Sarcoma, Alveolar Soft Part, Renal Cell Carcinoma, Melanoma
- Trial name
- NCT00258687
- Testing
- GVAX
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Dana-Farber Cancer Institute
Metastatic Clear Cell Renal Cell Carcinoma
[18F] PSMA-1007 PET/CT in Metastatic Clear Cell Renal Cell Carcinoma
Staging of kidney cancer is primarily achieved by computerized tomography (CT) scans or magnetic resonance imaging (MRI). If a patient is found to have limited metastatic disease, surgical removal or radiation therapy could be…
- Trial name
- NCT06428708
- Testing
- [18F] PSMA-1007 PET/CT
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Western University
Carcinoma, Renal Cell
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension Study
The goal of this China extension study is to evaluate the efficacy and safety of pembrolizumab plus belzutifan plus lenvatinib or pembrolizumab/quavonlimab plus lenvatinib versus pembrolizumab plus lenvatinib as first-line…
- Trial name
- NCT05899049
- Testing
- Pembrolizumab, Belzutifan, Pembrolizumab/Quavonlimab
- Where
- 17 sites in China
- Volunteers
- 251 people
- Sponsor
- Merck Sharp & Dohme LLC
Locally Advanced or Metastatic Non-clear Cell Type Renal Cell Carcinoma
pazopanib_NCRCC,Ph2 STUDY
Recent advances in understanding the biology and genetics of renal cell carcinoma (RCC) have led to major therapeutic implications.
- Trial name
- NCT01538238
- Testing
- pazopanib
- Where
- South Korea
- Volunteers
- 10 people
- Sponsor
- Samsung Medical Center
Kidney Neoplasms
EPO906 Therapy in Patients With Advanced Kidney Cancer
This study will examine whether the investigational drug EPO906, given by intravenous infusion (IV directly into the vein), is effective in shrinking tumors and preventing the growth of cells that cause kidney cancer.
- Trial name
- NCT00035243
- Testing
- epothilone b
- Where
- 8 sites in United States, France
- Volunteers
- 53 people
- Sponsor
- Novartis Pharmaceuticals
Solid Tumors, Hematologic Malignancies
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
A study to evaluate the safety and tolerability of INCA036873 in participants with advanced solid tumors and hematological malignancies.
- Trial name
- NCT07195916
- Testing
- INCA036873
- Where
- 22 sites in United States, Australia and 3 more
- Volunteers
- 280 people
- Sponsor
- Incyte Corporation
Renal Clear Cell Carcinoma, HIF-2α
Predicting HIF-2α Levels in Clear Cell Kidney Cancer Using Machine Learning
This project aims to conduct a multicenter retrospective study to collect clinical, CT imaging, and pathological data from patients.
- Conditions
- Renal Clear Cell Carcinoma, HIF-2α, Radiomics, Nomogram
- Trial name
- NCT07332923
- Where
- China
- Volunteers
- 500 people
- Sponsor
- First Affiliated Hospital of Fujian Medical University
VHL - Von Hippel-Lindau Syndrome, VHL Gene Mutation
A Phase 2 Study of Belzutifan (PT2977, MK-6482) for the Treatment of Von Hippel Lindau (VHL) Disease-Associated Renal Cell Carcinoma (RCC) (MK-6482-004)
This study is designed to investigate belzutifan as a treatment for VHL disease associated RCC.
- Conditions
- VHL - Von Hippel-Lindau Syndrome, VHL Gene Mutation, VHL Syndrome, VHL Gene Inactivation
- Trial name
- NCT03401788
- Testing
- Belzutifan
- Where
- 11 sites in United States, Denmark and 2 more
- Volunteers
- 50 people
- Sponsor
- Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Metastatic Clear Cell Renal Cell Carcinoma
Phase II Study of Lutetium-177 Labeled Girentuximab in Patients With Advanced Renal Cancer
To determine the efficacy of multiple doses Lutetium-177-DOTA-girentuximab in patients with advanced clear cell renal cell carcinoma using RECIST criteria.
- Trial name
- NCT02002312
- Testing
- Lu-177-DOTA-girentuximab
- Where
- Netherlands
- Volunteers
- 14 people
- Sponsor
- Radboud University Medical Center
Locally Advanced or Metastatic Solid Tumors, NSCLC
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
This is a first-in-human study to evaluate the safety, tolerability, pharmacokinetics (PK), and anti-tumor activity of enzelkitug when administered as a single agent and in combination with atezolizumab or pembrolizumab in adult…
- Conditions
- Locally Advanced or Metastatic Solid Tumors, NSCLC, HNSCC, Melanoma
- Trial name
- NCT05581004
- Testing
- Enzelkitug, Atezolizumab, Pembrolizumab
- Where
- 32 sites in United States, Australia and 7 more
- Volunteers
- 165 people
- Sponsor
- Genentech, Inc.
Clear Cell Renal Cell Carcinoma, Metastatic Kidney Carcinoma
Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer
This phase I/II trial studies the side effects and best dose of entinostat when given together with aldesleukin and to see how well this works in treating patients with kidney cancer that has spread to other places in the body.
- Conditions
- Clear Cell Renal Cell Carcinoma, Metastatic Kidney Carcinoma, Stage III Renal Cell Cancer AJCC v7, Stage IV Renal Cell Cancer AJCC v7
- Trial name
- NCT01038778
- Testing
- Aldesleukin, Computed Tomography, Entinostat
- Where
- 4 sites in United States
- Volunteers
- 47 people
- Sponsor
- National Cancer Institute (NCI)
Ewing's Sarcoma, Osteosarcoma
Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors
The best treatment for recurrent cancers or those that do not respond to therapies is not known. Typically, patients with these cancers receive a combination of cancer drugs (chemotherapy), surgery, or radiation therapy.
- Conditions
- Ewing's Sarcoma, Osteosarcoma, Astrocytoma, Atypical Teratoid/Rhabdoid Tumor
- Trial name
- Aflac ST0901 (NCT01331135)
- Testing
- sirolimus
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Emory University